Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Connect Biopharma Holdings (CNTB) Non-Current Deffered Revenue (2023 - 2024)

Connect Biopharma Holdings' Non-Current Deffered Revenue history spans 2 years, with the latest figure at $632000.0 for Q4 2024.

  • For Q4 2024, Non-Current Deffered Revenue rose 56.05% year-over-year to $632000.0; the TTM value through Dec 2024 reached $632000.0, up 56.05%, while the annual FY2024 figure was $632000.0, 56.05% up from the prior year.
  • Non-Current Deffered Revenue for Q4 2024 was $632000.0 at Connect Biopharma Holdings, up from $405000.0 in the prior quarter.
  • Across five years, Non-Current Deffered Revenue topped out at $632000.0 in Q4 2024 and bottomed at $405000.0 in Q4 2023.